Additionally, antidiabetic medications such as metformin, thiazolidinediones (TZDs), dipeptidyl peptidase 4 (DPP-4) inhibitors, and sodium glucose cotransporter 2 (SGLT2) inhibitors are currently used to improve insulin sensitivity and glycemic control in individuals with metabolic diseases [6]. This evidence concerns the gene DPP4 and metabolic disease.